Clinical trials located in

Padua

Padua city is located in Italy. Currently, 9 clinical trials are being conducted in this city.

Padua, located in the Veneto region of Italy, is a city steeped in history and culture. Known for its prestigious University of Padua, founded in 1222, it’s one of the oldest in the world, where Galileo Galilei once lectured. The city’s heart is the Prato della Valle, Europe’s largest square, surrounded by a moat and statues of notable figures. Padua is also famous for the Scrovegni Chapel, adorned with Giotto’s 14th-century frescoes, a masterpiece of Western art. Additionally, Saint Anthony of Padua, the patron saint of lost and stolen articles, is entombed here, making the city a significant religious site.

  • CT-EU-00021349

    Stomach cancer treatment comparison: trastuzumab deruxtecan vs. ramucirumab & paclitaxel

    This is a thorough comparison study to measure the effectiveness and safety of two treatment paths. It’s designed for individuals who have experienced progression regarding a stomach (gastric) cancer, or cancer of the gastro-esophageal junction (GEJ). The study focuses on those with HER2-positive gastric or GEJ who have previously undergone a trastuzumab-containing regime but have not received further systemic therapy.The research compares the use of trastuzumab deruxtecan, a potent anti-cancer agent, and the combined use of ramucirumab and paclitaxel. The study’s primary goal is to evaluate the overall survival rate, while secondary aims involve examining progression-free survival, response duration, disease control, safety, pharmacokinetics, and immunogenicity.In the study, participants are fairly and randomly assigned to receive one of two treatments. This is crucial in understanding the superiority and safety of these treatment paths, and this knowledge may inform future approaches to treating these types of cancer.

    • Ramucirumab
    • Trastuzumab deruxtecan
    • Paclitaxel
  • Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    • Tozorakimab
  • Study of trastuzumab deruxtecan in gastric cancer or gastroesophageal junction adenocarcinoma

    The aim of the DESTINY-Gastric04 study is to help cancer patients suffering from certain diseases. These patients have a specific type of stomach cancer or adenocarcinoma of the gastroesophageal junction that has not responded to treatment or has gotten worse after treatment with a medicine called trastuzumab. This study is testing a new drug called trastuzumab deruxtecan, comparing it with a combination of two other drugs – ramucirumab and paclitaxel. A key goal of this study is to determine how long participants will live after starting a new treatment. It will also be observed whether the cancer will shrink or stop growing, how long it will last, what the potential side effects of treatment will be and how the body will respond to the new drug.

    • Ramucirumab
    • Trastuzumab deruxtecan
    • Paclitaxel
  • Studying atenativ’s effectiveness in congenital antithrombin deficiency

    This study is designed to evaluate a new medication named Atenativ, intended for individuals with congenital antithrombin deficiency, a condition where the blood tends to form clots too easily. The study aims to assess the potential utility of Atenativ, particularly during situations such as surgery or childbirth, where there is an increased risk of blood clotting. The primary focus of the study is to determine the frequency of blood clot occurrences in individuals using Atenativ. Additionally, the research will investigate the pharmacokinetics of Atenativ, including its duration of presence in the body, elimination rate, and its impact on blood and clotting tests. Throughout the study, any side effects or adverse reactions experienced by individuals taking the medication will be carefully documented.

    • Atenativ
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • New method to boost drug’s efficacy against brain cancer

    This study is testing a special device called SonoCloud-9, which is used in combination with a common chemotherapy drug, carboplatin, in people with a specific type of brain cancer called glioblastoma multiforme that has relapsed. The brain has a type of wall, called the blood-brain barrier, which prevents many substances from entering the body, including chemotherapy drugs. The SonoCloud-9 device helps chemotherapy overcome this barrier using sound waves. Scientists hope this means that a larger dose of the drug will be able to fight brain cancer. This study will compare the results of this new approach with current standard treatments. Doctors will follow patients for up to 7 months and then visit them every 3 months until the study ends. They will measure the size of the tumor at the beginning and when they think it may grow again, and check survival rates at 12 and 18 months.

    • Lomustine
    • Temozolomide
    • Carboplatin
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Italy:

.